Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Seroquel XR in Schizophrenia
NCT00234377Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of quetiapine in schizophrenia, sponsored by AstraZeneca. Primary endpoint: Proportion of patients with improved clinical benefit at 12 weeks. Started Nov 2004; status: completed.
02
Drugs
quetiapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00234377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234377.